IMCODE004/BO45230 Urothelkarzinom der Harnblase (incl Nierenbecken, Ureter) (Aktiv)
XL184-021 Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors (Aktiv)
Zweitlinie oder später
BI 1403-0011 - BRIGHTLINE-2 Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of Brigimadlin (BI 907828) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours (Aktiv)
Basilea DZB-CS-201 (FIDES-02) Phase 1b/2 study of derazantinib and atezolizumab in patients with urothelial cancer (Aktiv)
Javelin A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination with Other Anti-Tumor Agents as a Maintenance Treatment in Participants with Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress with First Line Platinum-Containing Chemotherapy (Aktiv)
TROPHY U-01 A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer (Aktiv)